SNAP is a recently defined diagnostic category that comprises those individuals with abnormal neurodegeneration biomarkers (T‐tau and P‐tau181P) but without evidence of underlying amyloidosis (Jack et al, 2012) and might thus represent neurodegenerative diseases different from AD. Here, MAPT is linked to amyloidosis.